learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
Search
forLearn
5 / 801 resultslearn phosphorus
learn Phospholipids
learn L-Proline
learn threonine
Research
5 / 1000+ resultsresearch The Mammalian Hairless Protein as a DNA Binding Phosphoprotein
The Hr protein binds to DNA, interacts with p53, and affects cell cycle genes.
research Characterization of aberrant mTOR signaling pathway in U87MG glioblastoma cell line by quantitative phosphoproteomics
Inhibiting mTORC2 can reduce DNA repair and increase cancer cell death, suggesting potential for targeted brain cancer treatments.
research Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studies
Plucked human hair can be used to study drug effects on certain cell markers.
research The Hair Growth Effects of Wheat Bran
Wheat bran can boost hair growth by affecting cell cycle proteins and signaling pathways.
research Effect of Clitocybin A on the Proliferation of Dermal Papilla Cells
Clitocybin A from a mushroom may promote hair growth by increasing cell activity in hair follicles.
Community Join
5 / 1000+ resultscommunity Why doesn't phase 3 of PP405 start straight away?
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.
community My summation of PP405 - looks promising
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community New company created by Dr. Kang-Yell Choi to commercialize PTD-DBM therapy
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.
community PP405 Identity Research
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.